Differential effects of <i>RAS</i> mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer
Erina Haraguchi(Japanese Foundation For Cancer Research), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Shimpei Matsui(Keio University), Toshiki Mukai(Japanese Foundation For Cancer Research), Senzo Taguchi(Japanese Foundation For Cancer Research), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Tatsuki Noguchi(The University of Tokyo), Hiroshi Kawachi(Japanese Foundation For Cancer Research), Akiko Chino(Japanese Foundation For Cancer Research), Eiji Shinozaki(Japanese Foundation For Cancer Research), Takashi Akiyoshi(The Japanese Society of Gastroenterological Surgery), Masamichi Koyama, Takashi Sakamoto(Japanese Foundation For Cancer Research)
Cited by 2
Related Papers
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2021|411
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
|Cancer Science|2014|238